Psychedelic therapy using psilocybin, the psychoactive ingredient in hallucinogenic mushrooms, is becoming more accepted in European psychiatric treatment. Switzerland has begun offering psilocybin-assisted therapy to patients, and the Czech Republic has introduced carefully monitored treatment programs. Meanwhile, France restricts psilocybin use to clinical trials, pending further evidence of its effectiveness.
**Why this matters**
The gradual integration of psilocybin therapy into mental health care reflects growing interest in alternative treatments for conditions like depression and PTSD. However, regulatory bodies emphasize the need for rigorous oversight and more research to ensure safety and efficacy before widespread adoption.
Source: NewsData